The FDA on May 15, 2026, approved TECENTRIQ® (Atezolizumab) and TECENTRIQ HYBREZA® as adjuvant treatments for adults with Muscle Invasive Bladder Cancer (MIBC) after cystectomy who have circulating tumor DNA Molecular Residual Disease (ctDNA MRD) as determined by an FDA-authorized test. TECENTRIQ® and TECENTRIQ HYBREZA® are products of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
